Vivo Bio Tech Limited (BOM:511509)

Vivo Bio Tech Cash Flow Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Net Income	25.26	26.49	22.02	56.82	44.42
Depreciation & Amortization	71.98	71.68	59.32	46.9	51.72
Other Amortization	20.93	20.97	15.14	9.02	-
Other Operating Activities	62.53	62.84	28.11	-	-
Change in Accounts Receivable	-154.26	-61.55	12.51	15.33	-28.48
Change in Accounts Payable	128.78	27.9	29.32	13.69	18.43
Operating Cash Flow	155.22	148.34	166.42	141.76	86.07
Operating Cash Flow Growth	4.64%	-10.87%	17.40%	64.69%	-
Capital Expenditures	-79.5	-39.98	-511.12	-228.22	-102.34
Investing Cash Flow	-79.5	-39.98	-511.12	-228.22	-102.34
Long-Term Debt Issued	-	-	354.29	49.62	7.83
Long-Term Debt Repaid	-13.04	-69.87	-	-	-
Net Debt Issued (Repaid)	-13.04	-69.87	354.29	49.62	7.83
Issuance of Common Stock	-	27.86	31.37	38.21	13.1
Other Financing Activities	-62.53	-69.74	-35.48	-	-
Financing Cash Flow	-75.57	-111.75	350.18	87.83	20.93
Miscellaneous Cash Flow Adjustments	-	-	0	-	-
Net Cash Flow	0.15	-3.39	5.48	1.37	4.66
Free Cash Flow	75.72	108.36	-344.7	-86.46	-16.27
Free Cash Flow Growth	-30.12%	-	-	-	-
Free Cash Flow Margin	16.66%	20.75%	-67.07%	-16.70%	-2.94%
Free Cash Flow Per Share	4.54	7.31	-24.34	-6.38	-1.26
Cash Interest Paid	77.78	76.51	39.93	35.3	30.98
Cash Income Tax Paid	15.34	19.72	22.71	29.37	-1.88
Levered Free Cash Flow	-105.99	18.8	-390.38	-122.77	-39.47
Unlevered Free Cash Flow	-57.37	66.62	-365.42	-100.71	-21.91
Change in Net Working Capital	144.53	62.54	-18.94	3.85	16.9

Updated Jan 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.